Ocular regenerative therapies are on track to revolutionize treatment of numerous
blinding disorders, including corneal disease, cataract, glaucoma, retinitis pigmentosa,
and age-related macular degeneration. A variety of transplantable products, delivered
as cell suspensions or as preformed 3D structures combining cells and natural or artificial
substrates, are in the pipeline. Here we review the status of clinical and preclinical
studies for stem cell-based repair, covering key eye tissues from front to back, from
cornea to retina, and including bioengineering approaches that advance cell product
manufacturing. While recognizing the challenges, we look forward to a deep portfolio
of sight-restoring, stem cell-based medicine. VIDEO ABSTRACT.